CIK 0001213037
- Non-accelerated filer
- Smaller reporting company
Cardiff Oncology, Inc.
Sign in to watch- Ticker
- CRDF
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272004382
- Phone
- +1 858-952-7570
- Business address
- 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
- Former names
- Trovagene, Inc., TrovaGene Inc., XENOMICS INC, USED KAR PARTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 65 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-11 | Erlander Mark Chief Executive Officer | Grant or award · Stock Options | +758,400 | 2,925,098 | ||
| 2024-03-07 | Erlander Mark Chief Executive Officer | Grant or award · Stock Options | +510,000 | 2,170,310 | ||
| 2023-03-15 | Erlander Mark Chief Executive Officer | Grant or award · Stock Options | +482,064 | 1,664,477 | ||
| 2022-11-25 | Erlander Mark Chief Executive Officer | Purchase | +10,000 | $1.43 | $14K | 24,481 |
| 2022-03-09 | Erlander Mark Chief Executive Officer | Grant or award · Stock Options | +370,128 | 1,185,400 | ||
| 2021-06-10 | Erlander Mark Chief Executive Officer | Grant or award · Stock Options | +435,072 | 815,272 | ||
| 2021-03-23 | Erlander Mark Chief Executive Officer | Purchase | +965 | $10.34 | $10K | 14,481 |
| 2021-01-02 | Erlander Mark Chief Executive Officer | Option exercise | +260 | 13,629 | ||
| 2021-01-02 | Erlander Mark Chief Executive Officer | Shares withheld for taxes | −113 | 13,516 | ||
| 2021-01-02 | Erlander Mark Chief Executive Officer | Option exercise · Restricted Stock Units | −260 | 0 | ||
| 2020-06-17 | Erlander Mark Chief Executive Officer | Grant or award · Stock Options | +221,241 | 380,200 | ||
| 2020-05-14 | Erlander Mark Chief Executive Officer | Purchase | +6,993 | $1.43 | $10K | 13,369 |
| 2020-01-03 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −116 | 6,376 | ||
| 2020-01-03 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −552 | 6,231 | ||
| 2020-01-02 | Erlander Mark Chief Scientific Officer | Option exercise | +261 | 6,492 | ||
| 2020-01-02 | Erlander Mark Chief Scientific Officer | Option exercise · Restricted Stock Units | −261 | 260 | ||
| 2020-01-01 | Erlander Mark Chief Scientific Officer | Option exercise | +1,250 | 6,783 | ||
| 2020-01-01 | Erlander Mark Chief Scientific Officer | Option exercise · Restricted Stock Units | −1,250 | 521 | ||
| 2019-10-01 | Erlander Mark Chief Scientific Officer | Option exercise | +1,250 | 5,999 | ||
| 2019-10-01 | Erlander Mark Chief Scientific Officer | Shares withheld for taxes | −466 | 5,533 |
Page 1 of 3 · 60 trades